Viridian Therapeutics, Inc. (VRDN)
NASDAQ · Manufacturing · Pharmaceutical preparations
$20.87+$0.2100 (+1.02%) on the dayAs of the close; data may be delayed.
VRDN price, last 12 months
Key stats
- Previous close
- $20.66
- Open
- $21.00
- Day range
- $20.16 – $21.20
- 52-week range
- $13.18 – $34.29
- Volume
- 1.9M
- Avg volume (20 days)
- 1.6M
- Market cap
- $2.3B
Performance
1W−5.1%
1M−14.0%
3M+16.6%
6M−26.0%
YTD−32.9%
1Y+7.0%
vs S&P 500, 1Y−9.8 pts
Technicals and fundamentals
About Viridian Therapeutics, Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $2.3B